Physician profile
Srinivas Erragolla
NPI 1326127283
$6,291.05
in general payments reported to CMS, 2019-2025
34 companies · $1,734 in 2025
The $1,734 reported for 2025 was more than what 83% of Pain Medicine (Physical Medicine & Rehabilitation) providers received nationally (typical 2025 total: $400).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,602 · 2020: $193 · 2021: $1,136 · 2022: $764 · 2023: $438 · 2024: $424 · 2025: $1,734.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,422 · Travel and Lodging: $1,174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,421.83 |
| Travel and Lodging | $1,174.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,328.90 | 2021-2025 | Fusion, Intellis Adaptivestim, Inceptiv |
| Stryker Corporation | $1,045.27 | 2025 | Optablate |
| Boston Scientific Corporation | $917.04 | 2019-2025 | General - Pain Management |
| Collegium Pharmaceutical, INC. | $568.20 | 2019-2025 | Belbuca, Xtampza |
| Abbvie INC. | $420.13 | 2022-2025 | |
| Amgen INC. | $271.58 | 2019-2022 | |
| Pfizer INC. | $244.21 | 2019-2024 | |
| Medtronic USA, INC. | $227.48 | 2019 | |
| Arbor Pharmaceuticals, INC. | $195.99 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $141.17 | 2022 | |
| Lilly USA, LLC | $126.70 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $93.84 | 2019-2020 | |
| Nevro Corp. | $86.03 | 2019 | |
| Abbott Laboratories | $81.93 | 2021-2022 | |
| Painteq LLC | $45.31 | 2023-2024 | Painteq |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $41.28 | 2021 | |
| Vertos Medical, INC. | $40.82 | 2019 | |
| Orexo US, INC. | $40.55 | 2020-2021 | |
| Indivior INC. | $36.27 | 2024-2025 | Sublocade |
| Biodelivery Sciences International, INC. | $34.49 | 2021 | |
| Hikma Pharmaceuticals USA | $32.99 | 2022 | |
| Depuy Synthes Sales INC. | $31.02 | 2024-2025 | Orthovisc, Monovisc |
| Globus Medical, INC. | $29.40 | 2025 | Senza |
| Scilex Pharmaceuticals INC. | $28.92 | 2019 | |
| Alkermes, INC. | $28.82 | 2023 | Vivitrol |
| Teva Pharmaceuticals USA, INC. | $24.17 | 2020 | |
| Averitas Pharma INC. | $19.81 | 2024 | Qutenza |
| Kaleo, INC. | $19.31 | 2019 | |
| Grt US Holding, INC. | $17.04 | 2022 | |
| Forte Bio-Pharma LLC | $15.36 | 2024 | Prolate, Nalocet |
| Vertex Pharmaceuticals Incorporated | $15.00 | 2024 | |
| Allergan, INC. | $14.99 | 2021 | |
| Daiichi Sankyo INC. | $14.90 | 2019 | |
| Si-Bone, INC. | $12.13 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Srinivas Erragolla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.